PMC:7696151 / 69825-71041 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue	tao:has_database_id
2028	449-454	Gene	denotes	IFN-α	Gene:111654
2029	36-44	Species	denotes	patients	Tax:9606
2030	196-202	Species	denotes	murine	Tax:10090
2031	901-909	Species	denotes	patients	Tax:9606
2032	991-999	Species	denotes	patients	Tax:9606
2033	1069-1077	Species	denotes	patients	Tax:9606
2034	1190-1198	Species	denotes	patients	Tax:9606
2035	46-49	Chemical	denotes	HCQ	MESH:D006886
2036	146-149	Chemical	denotes	HCQ	MESH:D006886
2037	230-233	Chemical	denotes	HCQ	MESH:D006886
2038	844-851	Chemical	denotes	aspirin	MESH:D001241
2039	853-856	Chemical	denotes	HCQ	MESH:D006886
2040	1096-1103	Chemical	denotes	aspirin	MESH:D001241
2041	1111-1114	Chemical	denotes	HCQ	MESH:D006886
2042	15-35	Disease	denotes	rheumatoid arthritis	MESH:D001172
2043	66-85	Disease	denotes	lupus erythematosus	MESH:D008180
2044	95-113	Disease	denotes	autoimmune disease	MESH:D001327
2045	125-144	Disease	denotes	lupus erythematosus	MESH:D008180
2046	212-217	Disease	denotes	lupus	MESH:D008180
2047	486-491	Disease	denotes	lupus	MESH:D008180
2048	643-648	Disease	denotes	lupus	MESH:D008180
2049	915-920	Disease	denotes	lupus	MESH:D008180
2050	940-950	Disease	denotes	thrombotic	MESH:D013927
2051	1018-1046	Disease	denotes	cardiovascular complications	MESH:D002318
2052	1161-1168	Disease	denotes	thrombo	MESH:D054556
2053	1204-1209	Disease	denotes	lupus	MESH:D008180

Id	Subject	Object	Predicate	Lexical cue	hp_id
T129	15-35	Phenotype	denotes	rheumatoid arthritis	http://purl.obolibrary.org/obo/HP_0001370
T130	95-113	Phenotype	denotes	autoimmune disease	http://purl.obolibrary.org/obo/HP_0002960

Id	Subject	Object	Predicate	Lexical cue
T444	0-114	Sentence	denotes	In addition to rheumatoid arthritis patients, HCQ is also used in lupus erythematosus, another autoimmune disease.
T445	115-165	Sentence	denotes	Regarding lupus erythematosus, HCQ is widely used.
T446	166-505	Sentence	denotes	In vivo studies on a NZB/W F1 murine model of lupus showed that HCQ in combination with PRD (2.5 mg/kg/day and 1 mg/kg/day p.o.) decreased autoantibody production, as well as being able to inhibit toll-like receptor activation, resulting in the down-regulation of type I interferon (IFN-α) which is deeply implicated in lupus pathogenesis.
T447	506-814	Sentence	denotes	The efficacy of treatment is due to the ability of drugs to alter the expression of urinary and immune cell micro RNA that contribute to lupus progression by post-transcriptional modulation of genes involved in the immune response, pro-inflammatory cytokines production and toll-like receptor pathways [129].
T448	815-921	Sentence	denotes	In association with low-dose aspirin, HCQ is also indicated for thromboprophylaxis in patients with lupus.
T449	922-1216	Sentence	denotes	The occurrence of thrombotic events was recorded for 13 years in 189 patients, showing that the cardiovascular complications were more frequent in patients treated only with aspirin, while HCQ (up to 600 mg) was associated with a stronger thrombo-protective effect in patients with lupus [130].